US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,427.37

-6.4022-0.45%

Number of Gainers:13

Number of Losers:7

Number of Flat:- -

PE:- -

High:1,435.08

Open:1,435.08

Low:1,419.99

Close:1,433.74

Loading ...

Cadrenal Therapeutics Inc - Abbott to Share Insights From Heartmate 3 Trials

THOMSON REUTERS

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

ACCESS Newswire

Abbott : Citigroup Raises Target Price to $160 From $135

THOMSON REUTERS

Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Simply Wall St.

Citi ups Abbott target, opens ‘negative catalyst watch’

Bertrandt AG Managerial Share Purchase Signals Confidence

AstraZeneca (AZN) Receives a Buy from Bernstein

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today

Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug

AHCO vs. ABT: Which Stock Is the Better Value Option?

Pfizer could use existing US manufacturing to counter potential tariff hit

Ocugen's Gene Therapies Receive EMA Advanced Therapy Classification for Vision Loss Treatment

MT Newswires Live

Gilead Sciences sets aside $200 million to resolve HIV drug probe

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK4568/news?page=16"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4568"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1427.341,"timestamp":1741979647870,"preClose":1433.7432,"halted":0,"volume":52939432,"delay":0,"changeRate":-0.004465,"change":-6.402222,"pbRate":3.944289,"amount":2988891978.884415,"amplitude":0.010528,"prevYearClose":1274.8187,"fiveDayClose":1480.0557,"twentyDayClose":1396.8896,"turnoverRate":0.003423,"marketCap":1176207383991,"floatMarketCap":1155941651704,"peRate":31.483445},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1435.0837,"amplitude":0.010528,"preClose":1433.7432,"low":1419.9891,"pbRate":"3.944289","latestPrice":1427.3688,"volume":52940751,"delay":0,"open":1435.0837,"prevYearClose":1274.8187,"prevWeekClose":1480.0557,"prevMonthClose":1463.5875,"prevQuarterClose":1274.8187,"fiveDayClose":1480.0557,"twentyDayClose":1396.8896,"sixtyDayClose":1278.7518,"secType":"PLATE","market":"US","turnoverRate":0.003423,"peRate":31.483445,"marketCap":1176207383991,"floatMarketCap":1155941651704,"timestamp":1741979648825,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":13,"down":7,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:16,pageCount:16,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516754306","title":"Cadrenal Therapeutics Inc - Abbott to Share Insights From Heartmate 3 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2516754306","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516754306?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA76BCYD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0122379950.USD","IE00BJJMRZ35.SGD","SGXZ23171101.USD","LU0170899867.USD","LU2237957811.SGD","LU1721429402.USD","IE00BJT1NW94.SGD","BK4585","LU2089984988.USD","BK4566","BK4588","IE0009355771.USD","SG9999002224.SGD","LU2237957902.USD","LU1691799644.USD","IE0002141913.USD","IE00B2B36J28.USD","BK4082","LU0234572021.USD","LU1057294990.SGD","ABT","LU2133065610.SGD","IE00B4R5TH58.HKD","LU0266013472.USD","LU1989763427.SGD","LU2112291526.USD","BK4504","IE00BFTCPJ56.SGD","LU1989763690.USD","BK4581","LU1023059063.AUD","LU2468319806.SGD","CVKD","SG9999004303.SGD","BK4533","LU1061106388.HKD","BK4007","SG9999002232.USD","LU1721429741.USD","LU1914381329.SGD","BK4568","BK4592","LU0868494617.USD"],"gpt_icon":0},{"id":"2516667640","title":"Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD","url":"https://stock-news.laohu8.com/highlight/detail?id=2516667640","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516667640?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093200,"startTime":"0","endTime":"0","summary":"Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3 LVAD patients. PONTE VEDRA, Fla., March 04, 2025----Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral Vitamin K antagonist , today announced the signing of a Collaboration Agreement with Abbott  to support Cadrenal’s pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices  trial.\"We are pleased to have the support of Abbott, a global healthcare leader, which further validates the advancement into late-stage clinical development of tecarfarin. This partnership strengthens our access to key clinical trial sites and enhances patient enrollment efforts,\" said Quang X. Pham, Chief Executive Officer, Cadrenal Therapeutics, Inc. \"Together, we have a unique opportunit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cadrenal-therapeutics-announces-collaboration-agreement-130000984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2089984988.USD","BK4592","LU0170899867.USD","SG9999004303.SGD","LU2468319806.SGD","IE00B2B36J28.USD","ODD","IE00BJT1NW94.SGD","BK4533","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU1721429402.USD","BK4007","ABT","SG9999002232.USD","LENZ","IE00B4R5TH58.HKD","LU1989763690.USD","IE00BJJMRZ35.SGD","CVKD","LU0234572021.USD","LU2133065610.SGD","BK4082","LU1057294990.SGD","LU1691799644.USD","LU1989763427.SGD","IE0002141913.USD","BK4183","SG9999002224.SGD","LU1023059063.AUD","LU0122379950.USD","LU1721429741.USD","BK4139","BK4585","LU2237957902.USD","BK4588","IE0009355771.USD","LU2237957811.SGD","BK4568","SGXZ23171101.USD","LU0868494617.USD","LU1914381329.SGD","LU2112291526.USD","BK4566","BK4504","BK4581","LU0266013472.USD"],"gpt_icon":0},{"id":"2516620121","title":"CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2516620121","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516620121?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:00","pubTimestamp":1741089600,"startTime":"0","endTime":"0","summary":"LA JOLLA, Calif., March 4, 2025 /PRNewswire/ -- CalciMedica Inc.  , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium  channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announcedthat Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica, delivered a plenary presentation at the 30th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference  on March 3, 2025 in San Diego, CA. The presentation outlined the role of CRAC channels in acute kidney injury  pathophysiology and included new data highlighting the potential of CalciMedica's lead product candidate, Auxora, in AKI. CalciMedica is currently conducting a Phase 2 trial of Auxora in patients with Stage 2 or Stage 3 AKI and acute hypoxemic respiratory failure, which is expected to read out in 2025.In clinical trial biomarker studies, CARDEA patients who received Auxora versus placebo had","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/calcimedica-presents-aki-data-post-120000286.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calcimedica-presents-aki-data-post-120000286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4212","POST","BK4568","BK4585","BK4551","CALC","BK4139","BK4535","AP","BK4007","BK4006","BK4588","BK4548","BNTX"],"gpt_icon":0},{"id":"2516271126","title":"Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan","url":"https://stock-news.laohu8.com/highlight/detail?id=2516271126","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516271126?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:30","pubTimestamp":1741087800,"startTime":"0","endTime":"0","summary":"SHELTON, CT / ACCESS Newswire / March 4, 2025 / The HHS Department Secretary Robert F. Kennedy Jr. wrote an Opinion piece in the FoxNews entitled \"Measles outbreak is call to action for all of us\". He identifies an important issue that, \"…there is no approved antiviral for those who may be infected…\"We applaud Secretary Kennedy for recognizing the urgency of the situation and taking all possible steps including promoting vaccination in response to this outbreak, while clearly recognizing the deficiency in the response to be the lack of an effective treatment for measles viral disease,\" said Anil R. Diwan, PhD., President of NanoViricides, Inc.We note that the current efforts at containment with case-tracking, contact-tracing and isolation, face daunting challenges to be effective because measles is far more contagious than SARS-CoV-2 that caused the global COVID pandemic. In fact, measles is the most contagious disease known to humans. Also, a person may be contagious several days befo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/measles-outbreak-nv-387-promises-113000537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","HHS","BK4009","NNVC","BK4568"],"gpt_icon":0},{"id":"2516622883","title":"Abbott : Citigroup Raises Target Price to $160 From $135","url":"https://stock-news.laohu8.com/highlight/detail?id=2516622883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516622883?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:13","pubTimestamp":1741086823,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN05D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B4R5TH58.HKD","LU2237957902.USD","LU0266013472.USD","IE0009355771.USD","BK4592","LU0234572021.USD","BK4588","LU2468319806.SGD","SG9999002232.USD","LU1989763690.USD","LU0170899867.USD","LU2089984988.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU1721429402.USD","SG9999004303.SGD","LU1914381329.SGD","IE00B2B36J28.USD","LU1057294990.SGD","LU1721429741.USD","LU2237957811.SGD","BK4585","BK4568","LU2133065610.SGD","SGXZ23171101.USD","BK4504","BK4082","SG9999002224.SGD","ABT","LU0868494617.USD","LU1023059063.AUD","IE0002141913.USD","LU1061106388.HKD","IE00BJT1NW94.SGD","BK4533","LU1691799644.USD","BK4566","IE00BJJMRZ35.SGD","LU2112291526.USD","BK4581","LU1989763427.SGD"],"gpt_icon":0},{"id":"2516627913","title":"Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516627913","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516627913?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:00","pubTimestamp":1741086021,"startTime":"0","endTime":"0","summary":"Abbott Laboratories'  stock is up by a considerable 21% over the past three months. Since the market usually pay for a company’s long-term fundamentals, we decided to study the company’s key performance indicators to see if they could be influencing the market. In this article, we decided to focus on Abbott Laboratories'  ROE.Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.Return on Equity = Net Profit  ÷ Shareholders' Equity. So, based on the above formula, the ROE for Abbott Laboratories is:. A Side By Side comparison of Abbott Laboratories' Earnings Growth And 28% ROE. Is Abbott Laboratories Using Its Retained Earnings Effectively?The high three-year median payout ratio of 59%  for Abbott Laboratories suggests that the company's growth wasn't really hampered despite it returning most of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbott-laboratories-nyse-abt-stocks-110021096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJT1NW94.SGD","LU2112291526.USD","LU2089984988.USD","BK4581","IE00BJJMRZ35.SGD","BK4504","LU0234572021.USD","LU1914381329.SGD","LU1023059063.AUD","LU0170899867.USD","LU2468319806.SGD","NYSE","LU1057294990.SGD","BK4568","BK4082","LU0266013472.USD","LU1989763427.SGD","LU1721429402.USD","SG9999002232.USD","SG9999004303.SGD","LU2133065610.SGD","IE00BFTCPJ56.SGD","SG9999002224.SGD","BK4533","ABT","LU2237957902.USD","LU1721429741.USD","LU1989763690.USD","BK4588","BK4566","BK4592","LU1061106388.HKD","IE00B2B36J28.USD","SGXZ23171101.USD","LU1691799644.USD","IE0002141913.USD","IE0009355771.USD","LU0122379950.USD","LU0868494617.USD","LU2237957811.SGD","BK4585","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2516621292","title":"Citi ups Abbott target, opens ‘negative catalyst watch’","url":"https://stock-news.laohu8.com/highlight/detail?id=2516621292","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516621292?lang=en_us&edition=fundamental","pubTime":"2025-03-04 18:40","pubTimestamp":1741084851,"startTime":"0","endTime":"0","summary":"Citi raised the firm’s price target on Abbott (ABT) to $160 from $135 and keeps a Buy rating on the shares. The analyst also added a “90-day negati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citi-ups-abbott-target-opens-negative-catalyst-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citi-ups-abbott-target-opens-negative-catalyst-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","LU2112291526.USD","ABT","BK4566","IE00BFTCPJ56.SGD","BK4588","BK4082","SG9999002232.USD","LU2468319806.SGD","BK4581","LU2237957902.USD","BK4533","LU1057294990.SGD","LU1989763690.USD","LU1061106388.HKD","LU1691799644.USD","LU1989763427.SGD","LU2237957811.SGD","SG9999002224.SGD","BK4585","LU1721429741.USD","LU1721429402.USD","BK4568","IE0009355771.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0234572021.USD","IE0002141913.USD","LU0122379950.USD","SG9999004303.SGD","LU0868494617.USD","SGXZ23171101.USD","BK4592","LU0266013472.USD","LU2089984988.USD","BK4504","LU1023059063.AUD","LU2133065610.SGD","LU0170899867.USD","IE00BJT1NW94.SGD","LU1914381329.SGD"],"gpt_icon":0},{"id":"2516664076","title":"Bertrandt AG Managerial Share Purchase Signals Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2516664076","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516664076?lang=en_us&edition=fundamental","pubTime":"2025-03-04 16:57","pubTimestamp":1741078652,"startTime":"0","endTime":"0","summary":"Bertrandt ( ($DE:BDT) ) has shared an update. Bertrandt AG announced a managerial transaction involving Dr. Andreas Fink, a member of the managing ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bertrandt-ag-managerial-share-purchase-signals-confidence?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bertrandt-ag-managerial-share-purchase-signals-confidence?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","AG","BK4588","BK4535","BNTX","BK4139","BK4548","BK4568","BK4585","BK4210"],"gpt_icon":0},{"id":"2516864148","title":"AstraZeneca (AZN) Receives a Buy from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2516864148","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516864148?lang=en_us&edition=fundamental","pubTime":"2025-03-04 15:56","pubTimestamp":1741074975,"startTime":"0","endTime":"0","summary":"In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £190...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/astrazeneca-azn-receives-a-buy-from-bernstein?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/astrazeneca-azn-receives-a-buy-from-bernstein?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","AZN","LU0320765992.SGD","LU1829250122.USD","BK4007","LU0889565916.HKD","BK4585","LU2462157665.USD","BK4568","LU2236285917.USD","LU2417539215.USD","LU2456880835.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2516958616","title":"Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts","url":"https://stock-news.laohu8.com/highlight/detail?id=2516958616","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516958616?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:50","pubTimestamp":1741042206,"startTime":"0","endTime":"0","summary":"In the latest market close, Gilead Sciences  reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile, the Dow experienced a drop of 1.48%, and the technology-dominated Nasdaq saw a decrease of 2.64%.The HIV and hepatitis C drugmaker's shares have seen an increase of 17.6% over the last month, surpassing the Medical sector's gain of 1.11% and the S&P 500's loss of 1.26%.The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings per share  are projected to be $1.73, reflecting a 231.06% increase from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $6.78 billion, indicating a 1.36% growth compared to the corresponding quarter of the prior year.The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research show","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-rises-market-225006380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2089984988.USD","BK4585","IE0002270589.USD","BK4139","BK4532","IE00B19Z3B42.SGD","LU1585245621.USD","LU1571399168.USD","IE00BZ1G4Q59.USD","BK4578","LU0058720904.USD","LU1066053197.SGD","LU1839511570.USD","LU0289739699.SGD","BK4568","GILD","LU1430594728.SGD","LU1066051498.USD","BK4566","IE00BKVL7J92.USD","BK4588","IE00B7SZLL34.SGD","LU0109394709.USD","BK4583","IE00BSNM7G36.USD","LU2087621335.USD","LU0320765992.SGD","LU2468319806.SGD","IE00B3T34201.USD","LU0889565916.HKD","LU0234570918.USD","IE00B19Z3581.USD","BK4550"],"gpt_icon":0},{"id":"2516696813","title":"Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2516696813","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516696813?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:45","pubTimestamp":1741041911,"startTime":"0","endTime":"0","summary":"In the latest trading session, Johnson & Johnson  closed at $167.28, marking a +1.37% move from the previous day. This move outpaced the S&P 500's daily loss of 1.76%. At the same time, the Dow lost 1.48%, and the tech-heavy Nasdaq lost 2.64%.Shares of the world's biggest maker of health care products witnessed a gain of 8.46% over the previous month, beating the performance of the Medical sector with its gain of 1.11% and the S&P 500's loss of 1.26%.Investors will be eagerly watching for the performance of Johnson & Johnson in its upcoming earnings disclosure. The company is predicted to post an EPS of $2.59, indicating a 4.43% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $21.66 billion, indicating a 1.29% upward movement from the same quarter last year.The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-market-dipped-johnson-johnson-224511883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1430594728.SGD","LU0345769631.USD","LU2468319806.SGD","LU1162221912.USD","LU1244550221.USD","BK4534","LU0795875086.SGD","IE0002141913.USD","JNJ","LU0234572021.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4585","LU1674673428.USD","LU2430703251.USD","LU0058720904.USD","LU0320765646.SGD","LU0882574055.USD","IE00B19Z3581.USD","LU1674673691.USD","IE00B4R5TH58.HKD","BK4568","LU0912757837.SGD","LU1506573853.SGD","LU2133065610.SGD","IE00BVYPNV92.GBP","LU1221951129.SGD","LU2347655156.SGD","LU2129689605.HKD","LU1244550577.SGD","LU1057294990.SGD","LU2592432038.USD","IE00B2B36J28.USD","LU1267930813.SGD","IE00BGHQF631.EUR","IE00B42XCP33.USD","LU1196500208.SGD","LU1061106388.HKD","LU2430703178.SGD","LU0114720955.EUR","IE00BJT1NW94.SGD","LU0122379950.USD","LU2505996681.GBP","SG9999001440.SGD","LU1732799900.SGD","IE0002270589.USD","IE00BSNM7G36.USD","LU0234570918.USD","IE0034235303.USD","BK4559"],"gpt_icon":0},{"id":"2516944666","title":"Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2516944666","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516944666?lang=en_us&edition=fundamental","pubTime":"2025-03-04 04:00","pubTimestamp":1741032000,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European Medicines Agency’s  Committee for Medicinal Products for Human Use .The CHMP recommended conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma . The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.A final decision is expected in the coming months.Regeneron’s shares have lost 30.5% in the past year compared with the medical-biomedical genetics industry’s decline of 6.7%.Regeneron Pharmaceuticals Stock Price, Consensus and EPS Surprise. Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote. REGN’s oncology franchise got a boost with the European Commission","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-gets-positive-chmp-opinion-200000419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2106854487.HKD","LU0289739699.SGD","RHHBY","IE00BZ1G4Q59.USD","BK4139","LU0234570918.USD","LU0053666078.USD","LU0114720955.EUR","LU1066053197.SGD","BK4007","LU1430594728.SGD","IE00B3T34201.USD","03165","CHMP","LU0320765992.SGD","LU1917777945.USD","LU2468319806.SGD","BMRN","LU2237438978.USD","LU2023250504.SGD","GILD","LU2089984988.USD","IE00B7SZLL34.SGD","BK4583","FL","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU0882574055.USD","BK4550","LU2087621335.USD","BK4585","LU0889565916.HKD","BK4568","LU2362540622.SGD","IE00B19Z3581.USD","BK4087","LU0823416689.USD","LU0058720904.USD","LU0109394709.USD","BK4532","BK4094","LU1585245621.USD","LU1066051498.USD","REGN","LU2362541513.USD","BK4566","LU1974910355.USD","LU1839511570.USD","IE00BKVL7J92.USD","IE0002270589.USD"],"gpt_icon":0},{"id":"2516654069","title":"AHCO vs. ABT: Which Stock Is the Better Value Option?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516654069","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516654069?lang=en_us&edition=fundamental","pubTime":"2025-03-04 00:40","pubTimestamp":1741020026,"startTime":"0","endTime":"0","summary":"Investors interested in Medical - Products stocks are likely familiar with AdaptHealth Corp.  and Abbott . But which of these two stocks offers value investors a better bang for their buck right now?We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.AHCO currently has a forward P/E ratio of 10.25, while ABT has a forward P/E of 26.82. We also note that AHCO has a PEG ratio of 1.12. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. ABT currently has a PEG ratio of 2.57.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ahco-vs-abt-stock-better-164026618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1691799644.USD","BK4175","LU2112291526.USD","BK4533","LU1989763427.SGD","LU1057294990.SGD","LU2237957902.USD","LU0170899867.USD","IE0002141913.USD","LU2237957811.SGD","SGXZ23171101.USD","LU1989763690.USD","IE00BJJMRZ35.SGD","BK4566","LU0266013472.USD","BK4581","ABT","LU1023059063.AUD","LU2089984988.USD","SG9999004303.SGD","LU1721429741.USD","IE00BJT1NW94.SGD","LU0234572021.USD","SG9999002232.USD","AHCO","LU0868494617.USD","LU0122379950.USD","SG9999002224.SGD","LU1914381329.SGD","BK4082","IE00B2B36J28.USD","BK4504","BK4568","IE00BFTCPJ56.SGD","BK4585","BK4588","LU1721429402.USD","LU2133065610.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU2468319806.SGD","BK4592","LU1061106388.HKD"],"gpt_icon":0},{"id":"2516483653","title":"Pfizer could use existing US manufacturing to counter potential tariff hit","url":"https://stock-news.laohu8.com/highlight/detail?id=2516483653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516483653?lang=en_us&edition=fundamental","pubTime":"2025-03-04 00:23","pubTimestamp":1741018996,"startTime":"0","endTime":"0","summary":"UPDATE 2-Pfizer could use existing US manufacturing to counter potential tariff hitAdds background in paragraphs 5-8By Christy Santhosh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL3N3PM17A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0321505439.SGD","LU0456855351.SGD","IE000M9KFDE8.USD","LU0170899867.USD","LU0321505868.SGD","LU0289739699.SGD","IE00BLSP4452.SGD","LU0985481810.HKD","LU1057294990.SGD","IE00BLSP4239.USD","LU0306806265.USD","SGXZ57979304.SGD","BK4534","LU0058720904.USD","LU0868494617.USD","BK4533","LU1023059063.AUD","IE0002270589.USD","SG9999003800.SGD","SG9999001176.USD","LU0234572021.USD","SG9999001176.SGD","BK4588","LU1066051498.USD","LU1894683264.USD","SG9999011175.SGD","IE00BBT3K403.USD","BK4599","SG9999002224.SGD","PFE","SG9999013999.USD","SG9999002232.USD","LU0306807586.USD","LU1066053197.SGD","BK4585","BK4550","IE00B19Z3B42.SGD","LU1894683348.USD","BK4568","LU0225284248.USD","BK4007","LU1883839398.USD","BK4581","LU0122379950.USD","LU0225771236.USD","BK4592"],"gpt_icon":1},{"id":"2516653170","title":"Ocugen's Gene Therapies Receive EMA Advanced Therapy Classification for Vision Loss Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653170","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653170?lang=en_us&edition=fundamental","pubTime":"2025-03-04 00:22","pubTimestamp":1741018934,"startTime":"0","endTime":"0","summary":"Ocugen  said Monday that the European Medicines Agency's Committee for Advanced Therapies issued a positive opinion granting Advanced Therapy Medicinal Product classification for its OCU410 and OCU410ST gene therapy candidates, which are being developed to treat vision loss caused by geographic atrophy and Stargardt disease.Dosing in the Phase 2 portion of the OCU410 clinical trial has been completed, and Ocugen expects to begin a Phase 3 trial next year, with plans to pursue regulatory approval in the US and Europe in 2028.Last week, the US Food and Drug Administration endorsed Ocugen's plan to initiate a Phase 2/3 pivotal confirmatory trial for OCU410ST, which could support future biologics license and marketing authorization applications in the US and EU, respectively.If approved, OCU410 could become the first treatment available in Europe for geographic atrophy, a late-stage form of dry age-related macular degeneration. While two therapies are currently approved in the US, neither ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B7SZL793.SGD","AEIS","BK6522","BK4563","IE0031619046.USD","IE00B66KJ199.SGD","BK4157","BLZ.SI","IE00B19Z4B17.USD","BK6088","BK4139","OCGN","BK4568"],"gpt_icon":0},{"id":"2516653634","title":"Gilead Sciences sets aside $200 million to resolve HIV drug probe","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653634","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653634?lang=en_us&edition=fundamental","pubTime":"2025-03-04 00:18","pubTimestamp":1741018712,"startTime":"0","endTime":"0","summary":"Gilead Sciences sets aside $200 million to resolve HIV drug probeBy Luc Cohen NEW YORK, March 3 (Reuters) - Gilead Sciences GILD.O set aside $200 million for a potential settlement with federal prosec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL2N3PM0KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","LU1839511570.USD","LU2468319806.SGD","GILD","IE00BSNM7G36.USD","IE0002270589.USD","LU0234570918.USD","BK4550","LU1571399168.USD","BK4578","LU0109394709.USD","IE00B19Z3581.USD","LU0320765992.SGD","LU0889565916.HKD","LU1066051498.USD","LU1430594728.SGD","BK4532","BK4139","BK4585","LU2087621335.USD","LU0058720904.USD","BK4588","IE00B3T34201.USD","BK4568","IE00B7SZLL34.SGD","LU0289739699.SGD","BK4583","LU1066053197.SGD","BK4566","IE00BKVL7J92.USD","LU1585245621.USD"],"gpt_icon":0}],"pageSize":16,"totalPage":18,"pageCount":16,"totalSize":285}]}}